J Allergy Clin Immunol:过敏性鼻炎的预测因子

2015-05-18 MedSci MedSci原创

过敏性鼻炎(AR)是最常见的慢性疾病之一,是指特应性个体接触变应原后,主要由IgE介导的介质(主要是组胺)释放,并有多种免疫活性细胞和细胞因子等参与的鼻黏膜非感染性炎性疾病,通常在20岁前发病。过敏性鼻炎是一个全球性健康问题,可导致许多疾病和劳动力丧失。但是目前由于缺乏长期的前瞻性研究,因此临床上关于该疾病的信息预测、风险情况和保护因素等资料依旧匮乏。Grabenhenrich LB等人就该问题进

过敏性鼻炎(AR)是最常见的慢性疾病之一,是指特应性个体接触变应原后,主要由IgE介导的介质(主要是组胺)释放,并有多种免疫活性细胞和细胞因子等参与的鼻黏膜非感染性炎性疾病,通常在20岁前发病。过敏性鼻炎是一个全球性健康问题,可导致许多疾病和劳动力丧失。但是目前由于缺乏长期的前瞻性研究,因此临床上关于该疾病的信息预测、风险情况和保护因素等资料依旧匮乏。Grabenhenrich LB等人就该问题进行了长达20年的出生队列研究,探究早期生活环境和生活方式与过敏性鼻炎的关系。

在1990年,一项“多中心过敏研究”纳入了来自5个德国城市的1314新生儿,研究者对参与者在19个时间点孩子情况进行评估。通过COX回归模型分析41个生命早期独立的因素与过敏性鼻炎(AR)发生间的关系,包括对气源性致敏原的敏化作用,同时将非过敏性鼻炎作以及AR加哮喘作为继发结局指标。

研究结果显示,在13,179人年观察中有290例诊断为过敏性鼻炎(AR)。当期有AR家族史时,其患AR的风险增加(aHR, 2.49; 95% CI, 1.93-3.21),荨麻疹也会使AR风险增加(aHR, 1.32; 95% CI, 1.00-1.74),同样哮喘也会增加AR风险(aHR, 1.29; 95% CI, 0.95-1.75)。而早期致敏原的敏化作用(aHR, 4.53; 95% CI, 3.25-6.32)、3岁内发生湿疹(aHR, 1.83; 95% CI, 1.38-2.42)、男性(aHR, 1.28; 95% CI, 1.02-1.61)以及夏季秋季出生(aHR, 1.26; 95% CI, 1.00-1.58)是从出生到20岁AR风险的独立预测因子。研究者没有观察到其他与AR相关的社会经济、环境、生活方式、妊娠、及出生相关因素。

研究结果表明,只有一些不能改变的因素如早期致敏原的敏化作用、湿疹发作史、以及过敏性鼻炎(AR)家族史等可以作为后代20年内AR的预测因子,而不是早期生活环境、生活方式等可以改变的因素。

原始出处:

Grabenhenrich LB, Keil T, Reich A, et al. Prediction and prevention of allergic rhinitis: A birth cohort study of 20 years. J Allergy Clin Immunol. 2015 .

本文系Medsci原创编译整理!转载需要先获得授权,并附原文链接。谢谢!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=186832, encodeId=a26018683235, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=418d1603809, createdName=jiuling, createdTime=Wed Apr 12 09:11:39 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046794, encodeId=0ddd2046e9490, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Apr 02 09:39:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310600, encodeId=b9671310600a7, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed May 20 09:39:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328874, encodeId=fac713288e4b2, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed May 20 09:39:00 CST 2015, time=2015-05-20, status=1, ipAttribution=)]
    2017-04-12 jiuling

    学习了谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=186832, encodeId=a26018683235, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=418d1603809, createdName=jiuling, createdTime=Wed Apr 12 09:11:39 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046794, encodeId=0ddd2046e9490, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Apr 02 09:39:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310600, encodeId=b9671310600a7, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed May 20 09:39:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328874, encodeId=fac713288e4b2, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed May 20 09:39:00 CST 2015, time=2015-05-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=186832, encodeId=a26018683235, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=418d1603809, createdName=jiuling, createdTime=Wed Apr 12 09:11:39 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046794, encodeId=0ddd2046e9490, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Apr 02 09:39:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310600, encodeId=b9671310600a7, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed May 20 09:39:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328874, encodeId=fac713288e4b2, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed May 20 09:39:00 CST 2015, time=2015-05-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=186832, encodeId=a26018683235, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=418d1603809, createdName=jiuling, createdTime=Wed Apr 12 09:11:39 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046794, encodeId=0ddd2046e9490, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Apr 02 09:39:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310600, encodeId=b9671310600a7, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed May 20 09:39:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328874, encodeId=fac713288e4b2, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed May 20 09:39:00 CST 2015, time=2015-05-20, status=1, ipAttribution=)]
    2015-05-20 膀胱癌

相关资讯

JAMA:舌下免疫疗法能用于过敏性鼻炎和哮喘的治疗

    据3月27日发表在《美国医学会杂志》JAMA上的一则研究披露,在一项对一种针对过敏性鼻炎和哮喘的疗法所做的检查中,研究人员在先前的研究中发现了适度的证据以支持用舌下免疫疗法来治疗这些疾病的做法,该疗法在欧洲已经获得使用但却没有在美国获得美国食品与药物管理局的批准。舌下免疫疗法涉及在一个较长的治疗期内在舌下给予水溶性过敏原并通过局部吸收使过敏个体脱敏以减少其过敏

儿童过敏性鼻炎和哮喘的关系

  近年来,上、下气道炎症的一致性已经引起广大学者的关注,特别是过敏性鼻炎(AR)和哮喘关系密切,两者在病因学、发病机制和病理学改变方面极为类似,治疗上也有高度相似性。   患儿,男,6岁,因咳嗽伴喘息3月余来我院哮喘门诊就诊,患儿多次于外院就诊,被诊断为“支气管哮喘”,予激素吸入、抗生素口服等治疗,症状控制不佳。我院哮喘门诊检查:胸片示双肺纹理增多,肺功

关注哮喘、过敏性鼻炎的个体化治疗

重症哮喘管理最新进展    来自英国伦敦帝国理工学院实验医学、国家心肺研究所钟建桓教授,其对2014年欧洲呼吸协会(ERS)/美国胸科协会(ATS)国际指南关于重症哮喘管理方面的重点信息进行介绍。 ①进一步优化吸入型糖皮质激素(ICS)/长效β2受体激动剂(LABA)的剂量,可考虑更高剂量的治疗性试验。②考虑应用低剂量口服糖皮质激素进行维持治疗,但需监测